Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 63

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 63
---
 the scope and validity
of third-party proprietary rights. Such litigation could result in substantial costs and diversion of effort by us. We may have to participate
in opposition proceedings before the Australian Patent and Trademark Office or another foreign patent office, or in interference proceedings
declared by the United States Patent and Trademark Office, to determine the priority of invention for patent applications filed by competitors.
Any such litigation interference or opposition proceeding, regardless of outcome, could be expensive and time consuming, and adverse determinations
in any such proceedings could prevent us from developing, manufacturing or commercializing our products and could have a material adverse
effect on our business, financial condition and results of operations.

As of June 30, 2025, the Company
also owns pending Australian trademark applications.

Patent Portfolio

The following table presents
our portfolio of patents and patent applications, including their current status and title. We currently own 34 patents.

Competition

The table below outlines existing drugs and therapies
used to treat the illnesses we aim to treat with our drug candidates.

  Company name       Ticker                                           Clinical stage                           Products /Indications                                                                                                                                                                                     Product Differences                                                     
  AAA /Novartis      SWX: NOVN                                        Commercial and Phase I to Phase III      Radioligand therapies for NET, prostate, glioblastoma, small cell lung cancer. Most recent product, Lutathera Lu177 Dotatate pediatric neuroendocrine cancer FDA approved ’24; Pluvicto (Lu177 PS...      Only focuses on peptides, no SdmAb or mAbs                              
  Telix              ASX: TLX                                         Commercial and Phase I to Phase III      Therapeutics and imaging for various cancers: prostate, kidney, brain. FDA fast tracking Pixclara 18F for glioma imaging ’24; Lead agent Illuccix (Ga68 PSMA-11) for prostate cancer imaging FDA ...      Product uses different small molecule and monoclonal antibody targets   
  Clarity            ASX: CU6                                         Phase I & Phase III                      Therapeutics and imaging for prostate, neuroendocrine and neuroblastoma                                                                                                                                   Focus on copper isotopes only                                           
  Point Bio          Nasdaq: PNT Acquired by Eli Lilly ’23 $1.4B      Phase I to Phase III                     Therapeutics for pan cancer targeting Fibroblast Activation Protein (FAP)                                                                                                                                 FAP targeting and Ac-225 in prostate with different targeting molecule  
  RayzeBio           Private Acquired by BMS ’